While these are certainly hallmark symptoms of Alzheimer’s disease and other types of dementia, they may also come about from taking certain medications. Before automatically assuming an inevitable diagnosis of dementia, review the following list of prescribed medicines that can cause similar adverse ...
coronavirus, not to mention the civil and political tensions that have been occurring at the same time. This level of uncertainty, instability, and loss can easily negatively color our day-to-day existence, rob us of joy, and as with many of our patients, cause us ...
People with dementia, especially those living in residential aged care facilities (RACFs), are at particularly high risk of medication harm. We sought to describe medications prescribed for a sample of people with dementia living in RACFs.A total of 351 residents with dementia aged over 65 ...
Falls are listed as the number one reason for trauma in older people at emergency departments and are the leading cause of injuries that result in older people being admitted to hospital [2]. The World Falls guidance includes medication review as part of its recommended multifactorial risk ...
And SGLT2 inhibitors such as empagliflozin and dapagliflozin were also considerably protective against new-onset dementia in T2DM patients. Insulin therapy is a promising therapy but some studies indicated that it may increase the risk of AD. Herbal medicines are helpful for cognit...
However, large body of evidence showed that chronic HRT could increase the risk of various chronic diseases (eg. dementia and hypertension), limiting its clinical use in menopause symptoms management. Hence, alternative therapy that is safe and effective is urgently needed. Danggui Buxue Tang (DBT...
Around eight million people in the European Union live with dementia, with Alzheimer's disease accounting for more than half of these cases, according to the Alzheimer Europe website. Eisai, in a statement, said it was "extremely disappointed with the CHMP's negative opinion". ...
5 This is likely to cause concern that the UK might engage in regulatory competition to retain investments and clinical trials by setting unsafe standards. Close ties between the MHRA and the EMA, including the harmonization of regulatory procedures, would help minimize inevitable disruptions stemming...
142 Poor supply chain management and surveillance not only open the door to allow SF medicines to permeate the supply chain, but also cause stock-outs that drive patients to purchase medicines from unregulated markets.142 Therefore, efforts to improve supply-chain management, surveillance, and ...
Lynn Kramer, Eisai’s chief clinical officer, called the decision “extremely disappointing”, adding that “there is a significant unmet need for new innovative treatment options that target an underlying cause of disease progression”. John Hardy, a neuroscience professor at University College London...